Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7.

Recent studies suggest that targeting transcriptional machinery can lead to potent and selective anti-cancer effects in cancers dependent on high and constant expression of certain transcription factors for growth and survival. CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex. Its function is required for both cell cycle regulation and transcriptional control of gene expression. CDK7 has recently emerged as an attractive cancer target since its inhibition leads to decreased transcript levels of oncogenic transcription factors, especially those associated with super-enhancers (SE). Here we describe a selective CDK7 inhibitor SY-1365, which is currently in clinical trials in populations of ovarian and breast cancer patients (NCT03134638). In vitro, SY-1365 inhibited cell growth of many different cancer types at nanomolar concentrations. SY-1365 treatment decreased MCL1 protein levels, and cancer cells with low BCL-XL expression were found to be more sensitive to SY-1365. Transcriptional changes in acute myeloid leukemia (AML) cell lines were distinct from those following treatment with other transcriptional inhibitors. SY-1365 demonstrated substantial anti-tumor effects in multiple AML xenograft models as a single agent; SY-1365-induced growth inhibition was enhanced in combination with the BCL2 inhibitor venetoclax. Anti-tumor activity was also observed in xenograft models of ovarian cancer, suggesting the potential for exploring SY-1365 in the clinic in both hematological and solid tumors. Our findings support targeting CDK7 as a new approach for treating transcriptionally addicted cancers.

[1]  M. McKeown,et al.  Antitumor synergy with SY-1425, a selective RARα agonist, and hypomethylating agents in retinoic acid receptor pathway activated models of acute myeloid leukemia , 2018, Haematologica.

[2]  K. Lei,et al.  Inhibition of cyclin‐dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis , 2018, Journal of cellular biochemistry.

[3]  T. Giordano,et al.  Transcriptional targeting of oncogene addiction in medullary thyroid cancer. , 2018, JCI insight.

[4]  D. Taatjes,et al.  The essential and multifunctional TFIIH complex , 2018, Protein science : a publication of the Protein Society.

[5]  R. Bernards,et al.  A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma , 2018, Cell Research.

[6]  R. Young,et al.  High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma. , 2018, The Journal of investigative dermatology.

[7]  J. Tyner,et al.  Super-Enhancers Promote Transcriptional Dysregulation in Nasopharyngeal Carcinoma. , 2017, Cancer research.

[8]  Astrid Gall,et al.  Ensembl 2018 , 2017, Nucleic Acids Res..

[9]  R. Young,et al.  Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression. , 2017, Cancer discovery.

[10]  Darren L. Smith,et al.  Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARα Dependency Targetable by SY-1425, a Potent and Selective RARα Agonist. , 2017, Cancer discovery.

[11]  Jeremy R. Jacobsen,et al.  Human TFIIH Kinase CDK7 Regulates Transcription-Associated Chromatin Modifications. , 2017, Cell reports.

[12]  Ann E. Sizemore,et al.  Computational correction of copy-number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells , 2017, Nature Genetics.

[13]  Zhenfeng Zhang,et al.  Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer , 2017, Molecular Cancer Therapeutics.

[14]  G. O'Neill,et al.  Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma , 2017, Oncogenesis.

[15]  R. Young,et al.  Transcriptional Addiction in Cancer , 2017, Cell.

[16]  F. Robert,et al.  The RNA Polymerase II CTD: The Increasing Complexity of a Low-Complexity Protein Domain. , 2016, Journal of molecular biology.

[17]  Ming-Rong Wang,et al.  Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma , 2016, Gut.

[18]  P. Sorger,et al.  Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs , 2016, Nature Methods.

[19]  R. Young,et al.  CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer , 2015, Cell.

[20]  D. Price,et al.  THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing. , 2015, Molecular cell.

[21]  Fei Chen,et al.  Stably paused genes revealed through inhibition of transcription initiation by the TFIIH inhibitor triptolide , 2015, Genes & development.

[22]  Yan Liu,et al.  Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor. , 2014, Cancer cell.

[23]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[24]  Bandana Sharma,et al.  CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer , 2014, Cell.

[25]  Sridhar Ramaswamy,et al.  Targeting transcription regulation in cancer with a covalent CDK7 inhibitor , 2014, Nature.

[26]  P. Kuzmič,et al.  Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance , 2013, Proceedings of the National Academy of Sciences.

[27]  J. Lis,et al.  Control of transcriptional elongation. , 2013, Annual review of genetics.

[28]  Henning Hermjakob,et al.  The Reactome pathway knowledgebase , 2013, Nucleic Acids Res..

[29]  Karl A. Merrick,et al.  A Cdk7-Cdk4 T-loop phosphorylation cascade promotes G1 progression. , 2013, Molecular cell.

[30]  David A. Orlando,et al.  Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes , 2013, Cell.

[31]  Chao Zhang,et al.  Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II , 2012, Nature Structural &Molecular Biology.

[32]  D. Ehmann,et al.  Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor , 2012, Proceedings of the National Academy of Sciences.

[33]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[34]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[35]  S. Edwards,et al.  Mcl‐1; the molecular regulation of protein function , 2010, FEBS letters.

[36]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[37]  Marco Foiani,et al.  Regulation of DNA repair throughout the cell cycle , 2008, Nature Reviews Molecular Cell Biology.

[38]  Stéphane Larochelle,et al.  Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. , 2007, Molecular cell.

[39]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Conaway,et al.  Phosphorylation of C-terminal domain of RNA polymerase II is not required in basal transcription , 1993, Nature.

[41]  Robert A. Copeland,et al.  Evaluation of enzyme inhibitors in drug discovery , 2013 .

[42]  E. Calura,et al.  GRAPH Interaction from pathway Topological Environment , 2013 .